Amrit Bhangoo
Pediatric Endocrinology · Long Beach, CANPI 1982882254
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,093 of the $139,635 with a category attached, or 62.4%. 36 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 33.8% of the total. 2025 is the largest year on record at $84,139, more than ten times the $4,600 reported in 2019. Among pediatric endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $411.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$47K
- Neurocrine Biosciences, Inc.$35K
- Novo Nordisk$28K
- Pfizer$9K
- Arbor Pharmaceuticals, Inc.$4K
- AbbVie$4K
- plus $13K from 30 others
Across 37 payments — averaging $4805.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- OPKO Pharmaceuticals, LLC$50K
- Biomarin Pharmaceutical Inc.$49K
- Ipsen Pharma SAS$30K
- IBSA Institut Biochimique SA$19K
- Novo Nordisk Health Care AG$15K
- Pfizer$13K
- plus $2K from 1 others
What the payments were for
- Consulting fees$32,44823%
- Speaking & faculty fees$87,09362%
- Travel & lodging$11,2958%
- Food & beverage$8,1766%
- Education$6230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 59 | $47,221 |
| Neurocrine Biosciences, Inc. | 28 | $34,908 |
| Novo Nordisk | 54 | $27,714 |
| Pfizer | 22 | $9,109 |
| Arbor Pharmaceuticals, Inc. | 20 | $4,392 |
| AbbVie | 25 | $3,591 |
| Dexcom, Inc. | 10 | $3,497 |
| Rhythm Pharmaceuticals, Inc. | 8 | $2,938 |
| Eton Pharmaceuticals, Inc. | 2 | $2,070 |
| AstraZeneca | 3 | $1,171 |
| Ascendis Pharma Endocrinology Inc | 17 | $618 |
| Sanofi-aventis U.S. LLC | 6 | $501 |
| Ipsen Biopharmaceuticals, Inc | 5 | $218 |
| Lilly USA, LLC | 11 | $212 |
| Medtronic(2 entities) | 8 | $203 |
| Kyowa Kirin, Inc. | 3 | $185 |
| Endo Pharmaceuticals Inc. | 1 | $174 |
| Travere Therapeutics, Inc. | 25 | $146 |
| Insulet Corporation | 5 | $123 |
| Tandem Diabetes Care, Inc. | 4 | $91 |
| BD | 2 | $72 |
| Abbott | 2 | $53 |
| BETA Bionics, Inc. | 2 | $53 |
| Ultragenyx Pharmaceutical Inc. | 2 | $49 |
| Ascensia Diabetes Care US Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 1 | $42 |
| Galen US Inc | 2 | $36 |
| Senseonics, Incorporated | 2 | $34 |
| Greenwich Biosciences, Inc. | 1 | $30 |
| Sequel Med Tech, LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Amgen | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Sobi, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOXZOGO 1.2mg$36,258
- CRENESSITY$24,642
- Sogroya$21,337
- NGENLA$5,930
- Triptodur$4,126
- DEXCOM CGM$3,347
- Lupron Depot$3,150
- Imcivree$2,739
- Alkindi$2,046
- KHINDIVI$2,046
- INCRELEX$2,046
- Norditropin$2,040
- VOXZOGO$1,218
- Strensiq$1,125
- TZIELD$214
- SUPPRELIN$174
- CRYSVITA$128
- SKYTROFA$110
How this compares
$139,635 in reported general payments places this provider in the 95th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Long Beach
- Juliana AustinLong Beach$17K
- Pablito NagpalaLong Beach$11K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Lynda PolgreenOrange$167K
- Kevin KaisermanWest Covina$150K
- Mitchell GeffnerLos Angeles$129K
- Stephen GitelmanSan Francisco$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.